211at-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-lysine as multicarriers

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Lindegren, Sture ^a   Karlsson, Börje ^a   Jacobsson, Lars ^a   Andersson, Håkan ^a   Hultborn, Ragnar ^a   Skarnemark, Gunnar ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BIOTIN; BIOTINAMIDOCAPROIC N SUCCINIMIDE; DRUG CARRIER; MONOCLONAL ANTIBODY I 125; N SUCCINIMIDYL 3 (TRIMETHYLSTANNYL)BENZOIC ACID; POLY DEXTRO LYSINE; POLYLYSINE; POLYLYSINE BIOTINAMIDOCAPROIC N HYDROXYSUCCINIMIDYL 3 AMINOBENZOATE I 125; POLYLYSINE BIOTINAMIDOCAPROIC N HYDROXYSUCCINIMIDYL 3 AMINOBENZOATE I 131; POLYLYSINE BIOTINAMIDOCAPROIC N HYDROXYSYCCINIMIDYL 3 AMINOBENZOATE AT 211; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOTINYLATION; CANCER RADIOTHERAPY; CHEMICAL MODIFICATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FILTER; ISOMER; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRETARGETED RADIOIMMUNOTHERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANIMALS; ASTATINE; BIOTIN; BIOTINYLATION; FEMALE; IMMUNOTHERAPY; KIDNEY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLYLYSINE; PROTEIN ISOFORMS; RADIOIMMUNOTHERAPY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0141679548     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Crippa, F., Bolis, G., Seregni, E., Gavoni, N., Scarfone, G., Ferraris, C., Buraggi, G. L., and Bombardieri, E. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur. J. Cancer, 31A: 686-690, 1995.
2. Goldenberg, D. M. The role of radiolabelled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol., 39: 191-201, 2001.
3. White, C. A., Weaver, R. L., and Grillo-López, A. J. Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med., 52: 125-145, 2001.
4. Stoldt, H. S., Aftab, F., Chinol, M., Paganelli, G., Luca, F., Testori, A., and Geragherty, J. G. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur. J. Cancer, 33: 186-192, 1997.
5. Sakahara, H., and Saga, T. Avidin-biotin for delivery of diagnostic agents. Adv. Drug Deliv. Rev., 37: 89-101, 1999.
6. Wilbur, D. S., Pathare, P. M., Hamlin, D. K., Stayton, P. S., To, R., Klumb, L. A., Buhler, K. R., and Vesella, R. L. Development of new biotin/streptavidin reagents for pretargeting. Biomol. Eng., 16: 113-118, 1999.
7. 90Y-DOTA-biotin. J. Nucl. Med., 41: 131-140, 1999.
8. Weiden, P. L., and Breitz, H. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit. Rev. Oncol. Hematol., 40: 37-51, 2001.
9. Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De Cicco, C., Fiorenza, M., Gatti, M., Calicceti, P., and Paganelli, G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer, 86: 207-212, 2002.
10. Sharkey, R. M., Karacay, H., Griffiths, G. L., Behr, T. M., Blumenthal, R. D., Mattes, M. J., Hansen, H. J., and Goldenberg, D. M. Development of streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjugate Chem., 8: 595-604, 1997.
11. Zhang, M., Yao, Z., Garmestani, K., Axworthy, D. B., Zhang, Z., Mallett, R. W., Theodore, L. J., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., and Waldman, T. A. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukaemia with the α-emitting radionuclide, bismuth 213. Blood, 100: 693-713, 2002.
12. Press. O. W., Corcoran, M., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L., Yau, E., Mallett, R., Meyer, D. L., and Axworthy, D. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD-20 expressing lymphoma xenografts. Blood, 98: 2535-2543, 2001.
13. Cremoneze, M., Ferrari, M., Chinol, M., Stabin, M. G., Grana, C., Pisco, G., Robertson, C., Tosi, G., and Paganelli, G. Three-step radioimmunotherapy with yttrium-90 biotin:dosimetry and pharmacokinetics in cancer patients. Eur. J. Nucl. Med., 26: 110-120, 1999.
14. 211At-labeled, biotinylated and charge modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy. Bioconjugate Chem., 13: 502-509, 2002.
15. Lindegren, S., Bäck, T., and Jensen, H. Dry-distillation from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl. Radiat. Isot., 55: 157-160, 2001.
16. Lindegren, S., Andersson, H., Bäck, T., Jacobsson, L., Karlsson, B., and Skarnemark, G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl. Med. Biol., 28: 33-39, 2001.
17. Cayot, P., and Tainturier, G. The quantification of protein amino groups by the trinitrobenzensulfonic acid method: a reexamination. Anal. Biochem., 249: 184-200, 1996.
18. Green, N. M. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem. J., 94: 23c-24c, 1965.
19. Wilbur, D. S., Hamlin, D. K., Pathare, P. M., and Weerawarna, S. A. Biotin reagents for antibody pretargeting. Synthesis radioiodination, and in vitro evaluation of biotinidase resistant biotin derivatives. Bioconjugate Chem., 8: 572-584, 1997.
20. Foulon, C. F., Alston, K. L., and Zalutsky, M. R. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl. Med. Biol., 25: 81-88, 1998.
21. Wilbur, D. S., Chyan, M-K., Pathatre, P. M., Hamlin, D. K., Frownfelter, M. B., and Kegley, B. B. Biotin reagents for antibody pretargeting. 4. Selection of biotin conjugates for in vivo application based on their dissociation from avidin and streptavidin. Bioconjugate Chem., 12: 616-623, 2000.
22. Wilbur, D. S., Hamlin, D. K., Kegley, B. B., and Pathatre, P. M. Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability. Bioconjugate Chem., 11: 569-583, 2001.
23. Wilbur, D. S. Potential use of α emmitting radionuclides in the treatment of cancer. Antibody Immunoconj. Radiopharm., 4: 85-97, 1991.
24. McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Juricic, J. G., Larson, S. M., and Scheinberg, D. A. Radioimmunotherapy with α-emitting nuclides, Eur. J. Nucl. Med., 25: 1341-1351, 1998.
25. Imam, S. K. Advancements in cancer therapy with α-emitters: A review. Int. J. Radiat. Oncol. Biol. Phys., 51: 271-278, 2001.
26. Zalutsky, M. R., And Bigner, D. D. Radioimmunotherapy with α-particle-immunoconjugates. Acta. Oncol., 35: 373-379, 1996.
27. 211At. Radiat. Res., 157: 633-641, 2002.
28. Zalutsky, M. R., and Vaidayanathan, G. Astatine-211-labelled radiotherapeutics: an emerging approach to targeted α particle radiotherapy. Curr. Pharm. Design, 6: 1433-1455, 2000.
29. 211At-labelled monoclonal antibody MOv18. Anticancer Res., 20: 459-462, 2000.
30. del Rosario, R. B., and Wahl, R. L. Biotinylated iodo-polylysine for pretargeted radiation delivery. J. Nucl. Med., 34: 1147-1151, 1992.
31. Torchilin, V. P. Biotin-conjugated polychelating agent. Bioconjugate Chem., 10: 146-149, 1999.
32. Li, L., Olafsen, T., Anderson, A-L., Wu, A., Raubitschek, A. A., and Shively, J. E. Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a cys-diabody. Bioconjugate Chem., 13: 985-995, 2002.
33. 211At]-astatide in normal tissues: preliminary evaluation of seven potential compounds. Nucl. Med. Biol., 25: 351-357, 1998.